Abstract: This invention provides a technique that is capable of suppressing variation in the amount of phospholipids obtained in each operation when a phospholipid concentrate is obtained by subjecting an ethanol extract concentrate of livestock or poultry tissue to a degumming step and collecting gum. More specifically, the invention provides a method for producing a phospholipid concentrate from livestock or poultry tissue, comprising step (A) of mixing an ethanol extract concentrate of livestock or poultry tissue with water, the water being in an amount of less than 7 parts by mass per 100 parts by mass of the concentrate, and step (B) of centrifuging the obtained liquid mixture at 2° C. or lower.

Abstract: This invention provides a technique that is capable of efficiently producing a phospholipid concentrate without using centrifugation and that is suitable for scaling up, the technique being for use in obtaining a phospholipid concentrate by subjecting an ethanol extract concentrate of bird breast meat to a degumming step and collecting gum. More specifically, the invention provides a method for producing a phospholipid concentrate, comprising a step of allowing a liquid mixture comprising an ethanol extract concentrate of bird breast meat and a 40 to 60 mass % aqueous ethanol solution in a mass ratio of 1:0.8 to 1.2 to stand at 40 to 60° C.

Abstract: This invention provides a technique that is capable of efficiently producing a phospholipid concentrate without using centrifugation and that is suitable for scaling up, the technique being for use in obtaining a phospholipid concentrate by subjecting an ethanol extract concentrate of bird breast meat to a degumming step and collecting gum. More specifically, the invention provides a method for producing a phospholipid concentrate, comprising a step of allowing a liquid mixture comprising an ethanol extract concentrate of bird breast meat and a 40 to 60 mass % aqueous ethanol solution in a mass ratio of 1:0.8 to 1.2 to stand at 40 to 60° C.

Abstract: This invention provides a technique that is capable of stably storing plasmalogen for a long period of time. More specifically, the invention provides a plasmalogen-containing solid composition comprising plasmalogen, ?-cyclodextrin, and a pH alkali adjusting agent, and having a pH of 6 to 8 when formed into a 1 mass % aqueous suspension.

Abstract: This invention provides a technique that is capable of suppressing variation in the amount of phospholipids obtained in each operation when a phospholipid concentrate is obtained by subjecting an ethanol extract concentrate of livestock or poultry tissue to a degumming step and collecting gum. More specifically, the invention provides a method for producing a phospholipid concentrate from livestock or poultry tissue, comprising step (A) of mixing an ethanol extract concentrate of livestock or poultry tissue with water, the water being in an amount of less than 7 parts by mass per 100 parts by mass of the concentrate, and step (B) of centrifuging the obtained liquid mixture at 2° C. or lower.

Abstract: An objective of the present invention is to provide a new substance having a cerebral nerve cell neogenesis effect. Another objective is to provide a cerebral nerve cell neogenesis agent that is effective in treating and/or preventing neurological disorders utilizing the substance. With the present invention, a cerebral nerve cell neogenesis agent containing a plasmalogen as an active ingredient is provided. In particular, a preferable cerebral nerve cell neogenesis agent contains, as an active ingredient, a biological tissue (preferably, an avian tissue) extracted plasmalogen mainly including an ethanolamine plasmalogen and a choline plasmalogen.

Abstract: This invention provides a process for producing a high-purity sphingomyelin and a high-purity plasmalogen-form glycerophospholipid from a biological material by simple procedures at high yields.

Abstract: An objective of the present invention is to provide a novel method with an effect of alleviating central nervous system inflammation. The present invention provides a drug against central nervous system inflammation containing a plasmalogen. More preferably, the present invention provides a drug against central nervous system inflammation containing a plasmalogen extracted from a biological tissue (preferably an avian tissue) that mainly contains an ethanolamine plasmalogen and a choline plasmalogen.

Abstract: Disclosed is a process for producing sphingomyelin and plasmalogen-form glycerophospholipid, which comprises the step (A) of extracting a total lipids from a chicken skin powder and drying the extract, the step (B) of subjecting the dried total lipids obtained in said step (A), to extraction treatment with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion, the step (C) subjecting the insoluble portion composed mainly of sphingomyelin, obtained in said step (B), to extraction treatment with a solvent mixture of water and a water-soluble ketone solvent to remove a non-lipid component contained in the soluble portion, and the step (D) of drying the soluble portion obtained in said step (B), and subjecting the thus-obtained dried product to extraction treatment with a water-soluble ketone solvent to separate and recover an insoluble portion composed mainly of plasmalogen-form giycerophosp

Abstract: This invention provides a process for producing a high-purity sphingomyelin and a high-purity plasmalogen-form glycerophospholipid from a biological material by simple procedures at high yields.